Xeno-Free Media

Xeno-free (XF) media is cell-culture medium formulated to contain no components derived from a species other than the one being cultured. For media used to grow human cells, that means human-derived supplements — human platelet lysate, human serum albumin, human recombinant growth factors — are permitted under a xeno-free designation, while material from any non-human animal (most commonly bovine, via fetal bovine serum) is excluded. The purpose is to remove the risk of xenogeneic contamination: viral and prion transmission from animal tissue, immune reactions to non-human antigens the cultured cells pick up from the medium (the classic example is Neu5Gc, a non-human sialic acid incorporated from bovine serum that can trigger an immune response when cells are used therapeutically in humans), and the lot-to-lot variability inherent to any animal-derived biological fluid.

For a procurement officer or lab manager evaluating suppliers, “xeno-free” is a specific, checkable claim — not a marketing label to take at face value. This page covers what the term actually requires, how it differs from adjacent terms suppliers use inconsistently, and what to verify before buying.

What “xeno-free” means, precisely

A medium qualifies as xeno-free when every raw material in the formulation has been checked against the species being cultured, and nothing of a different species’ origin is present. This is a relative, not an absolute, definition — it depends on what you’re culturing:

• For human cell culture (stem cells, primary cells, cell-therapy starting material), xeno-free means no non-human animal-derived components. Human-sourced material — human platelet lysate (hPL), human serum albumin, human transferrin — is compatible with a xeno-free claim, because it isn’t xenogeneic to a human cell.
• For animal cell culture (e.g., a veterinary or agricultural cell line), the same logic applies relative to that species — material from a different species is xenogeneic; material from the same species, or fully synthetic/recombinant material, is not.

This is the detail most worth double-checking with a supplier: “xeno-free” on a spec sheet does not by itself tell you whether the formulation still contains a biological component (human-derived or otherwise) or is fully synthetic/recombinant. Ask for the actual component list, not just the label.

Xeno-free vs. serum-free vs. animal-component-free vs. chemically defined

These four terms describe overlapping but distinct properties, and suppliers do not use them consistently — a procurement spec that just says “xeno-free” without further qualification is under-specified. The practical distinctions:

• Serum-free (SF) means no whole serum (e.g., no FBS) was added. It says nothing about whether individual purified animal-derived proteins — bovine serum albumin, bovine transferrin — are still present as separate additives. A serum-free medium can still be non-xeno-free.
• Xeno-free (XF) means no components from a species other than the one being cultured, as described above. A xeno-free medium for human cells may still contain human-derived biological material (hPL, human albumin) and therefore is not automatically animal-component-free.
• Animal-component-free (ACF), also called animal-origin-free (AOF), is the strictest of the three: no material derived from any animal species — including human — is present. Everything is either fully synthetic, plant-derived, or produced via recombinant expression (e.g., a growth factor manufactured in a microbial or non-animal cell-line system). ACF/AOF media are frequently, and correctly, also xeno-free, but the reverse is not true.
• Chemically defined (CD) describes exact, disclosed composition — every component and its concentration is known — rather than sourcing. A chemically defined medium is typically also xeno-free and ACF, but “chemically defined” and “xeno-free” answer different questions (what’s in it, vs. where it came from) and a formulation can in principle satisfy one without the other, e.g. an undefined proprietary hydrolysate blend that happens to be plant-derived and xeno-free but not chemically defined.

Because of this inconsistency, a purchasing specification should state the actual requirement (e.g., “no components of non-human animal origin, human-derived components acceptable, full component disclosure required on request”) rather than relying on a single marketing term to carry that meaning.

Why it matters: regulatory and manufacturing drivers

Xeno-free formulations exist because of two converging pressures on cell-based research and manufacturing:

• Risk of transmissible disease and immunogenicity. Animal-derived supplements, most notably fetal bovine serum, carry a documented (if low) risk of viral and prion contamination and a well-characterized risk of introducing non-human antigens like Neu5Gc into cells intended for human therapeutic use. Regulators and standards bodies treat this as a manufacturing-process risk to be minimized, not eliminated by testing alone.
• Regulatory expectations for cell and gene therapy manufacturing. For cellular and gene-engineered products intended for clinical use, ancillary materials — reagents like culture media, serum, and growth factors used during manufacture but not present in the final product — are expected to be sourced, tested, and documented to a standard proportional to their risk. Good Clinical Laboratory Practice (GCLP) and broader GxP quality frameworks both bear on this documentation expectation, and manufacturers increasingly specify xeno-free or ACF ancillary materials specifically to reduce the risk and testing burden associated with animal-derived inputs. ISO 20399, the international standard for ancillary materials used in cellular and gene-engineered product manufacture, sets out the documentation categories (origin, testing, traceability) that a xeno-free supplier should be able to satisfy.

Outside regulated manufacturing, research-grade xeno-free media are also widely used in stem-cell research (induced pluripotent stem cells and embryonic stem cells) and regenerative-medicine research even before a program reaches clinical translation, both to reduce variability between experiments and to keep an early-stage process compatible with eventual GMP scale-up rather than requiring a full reformulation later. CASRAI’s guide on the ethics of embryonic stem cell research covers the broader regulatory context stem-cell programs operate within, and the GMP guide for research institutions covers how ancillary-material sourcing decisions like this one fit into a GMP-track manufacturing process more generally.

What to evaluate before purchasing xeno-free media

Because “xeno-free” is applied inconsistently across suppliers and covers a wide range of actual formulations, a purchasing decision should be based on documented, verifiable criteria rather than the label alone:

• Full component disclosure. Ask for the actual formulation, or at minimum a species-of-origin statement for every biological component — not just a claim that the product “is xeno-free.” A supplier that cannot or will not disclose sourcing for each raw material is not a defensible basis for a regulated or research-critical process.
• Whether human-derived material is present, and if so, its own sourcing documentation. If the formulation includes human platelet lysate, human serum albumin, or another human-derived component, that component needs its own chain-of-custody, donor-screening, and viral-testing documentation — it is xeno-free but not risk-free, and not ACF.
• Origin of recombinant proteins. A recombinant growth factor or albumin is not automatically risk-free just because it isn’t a raw animal fluid — check what expression system produced it (bacterial, yeast, plant, or an animal cell line such as CHO) and whether animal-derived components (e.g., an animal-derived cell-culture supplement) were used anywhere upstream in its own manufacture.
• Grade: research-use-only vs. GMP-grade. Research-grade and GMP-grade xeno-free media are not interchangeable for a clinical-track program. GMP-grade products typically come with a Drug Master File (DMF) or equivalent regulatory filing the supplier can reference, tighter lot-release testing, and change-control notification — confirm which grade is actually being quoted.
• Lot-to-lot consistency and change-control notification. Ask how the supplier handles formulation changes and whether customers are notified before a reformulation ships. For a validated manufacturing process, an undisclosed formulation change can trigger unplanned re-validation work.
• Performance qualification against your specific cell type. Xeno-free formulations do not always perform identically to a serum-containing medium for a given cell type — growth kinetics, attachment, and, for stem cells, differentiation potential and pluripotency markers can differ. Run a qualification comparison against the current medium on the actual cell line or primary cells in use before committing to a full-scale switch, the same lot-qualification discipline used when evaluating any new cell-culture reagent (see CASRAI’s Fetal Bovine Serum entry for the equivalent qualification checklist on the serum side).
• Supply continuity and scale. For a manufacturing-scale program, confirm the supplier can provide the volumes and lot sizes needed at production scale, not just research-scale catalog quantities, and ask about lead time and any pre-qualified reserved-lot options.

None of this requires favoring one named commercial supplier over another — these are the criteria to request documentation against from any vendor being evaluated, and the actual basis for comparing quotes beyond price per liter.

What isn’t xeno-free media

A medium supplemented with fetal bovine serum (FBS) is the clearest non-example — FBS is bovine-derived and, for human cell culture, squarely xenogeneic. Less obviously: a medium labeled “serum-free” that still contains a purified animal-derived protein additive (bovine serum albumin is a common one) is not xeno-free, even though no whole serum was added — “serum-free” and “xeno-free” are not synonyms, as covered above. And a xeno-free medium containing human-derived components (human platelet lysate, human albumin) is not the same as an animal-component-free (ACF) medium, which excludes animal-derived material of any species, human included.

Related terms

See also CASRAI’s dictionary entry on Fetal Bovine Serum (FBS) and the guides on cell culture basics, cell cryopreservation, GxP compliance, and Good Manufacturing Practice (GMP) for research institutions for the broader quality and regulatory context xeno-free sourcing decisions sit within.

Frequently asked questions

What does “xeno-free” mean in cell culture media?

It means the medium contains no components derived from a species other than the one being cultured. For human cell culture, human-derived supplements (like human platelet lysate) are still compatible with a xeno-free claim; material from any non-human animal, such as fetal bovine serum, is not.

Is xeno-free the same as serum-free?

No. Serum-free only means no whole serum was added — a serum-free medium can still contain a purified animal-derived protein additive like bovine serum albumin, which would make it not xeno-free.

Is xeno-free the same as animal-component-free (ACF)?

No. Animal-component-free (also called animal-origin-free) is stricter — it excludes animal-derived material of any species, including human. A xeno-free medium for human cells may still legitimately contain human-derived components and therefore not qualify as ACF.

Why does xeno-free matter for cell and gene therapy manufacturing?

Animal-derived ancillary materials carry a documented risk of viral/prion contamination and can introduce non-human antigens (such as Neu5Gc from bovine serum) that provoke an immune response when the cultured cells are later used therapeutically in humans. Regulatory and quality frameworks for ancillary materials, including ISO 20399, expect this risk to be documented and, where feasible, minimized.

What should a buyer verify before purchasing xeno-free media?

Full species-of-origin disclosure for every biological component, whether any human-derived material is present and how it’s sourced/tested, the expression system behind any recombinant proteins, research-use-only vs. GMP grade, the supplier’s change-control notification practice, and a performance-qualification comparison against the specific cell type before switching at full scale.